Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

2.730 -0.180 (-6.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
InMed Pharmaceuticals (NASDAQ: INM) Defining Value of Rare Cannabinoids in Pharma Space
Via Investor Brand Network
Topics Cannabis
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space
Via Investor Brand Network
Topics Cannabis
InMed (NASDAQ: INM) Gains Potential to Synthetically Produce Rare Cannabinoids at Scale
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals' Issues Annual Shareholder Letter
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals (NASDAQ: INM) Leveraging Growing Cannabinoid-Based Pharma Market
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
Via CannabisNewsWire
Topics Cannabis
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
Via CannabisNewsWire
Topics Supply Chain
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Issues Annual Shareholder Letter
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
Via Investor Brand Network
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... 
Via Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
Via Investor Brand Network
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... 
Via Benzinga
Topics Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via CannabisNewsWire
Topics Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via Investor Brand Network
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS